{"entity": "publication", "iuid": "12838f3eef3e4b4b9c92c066ec0837b9", "timestamp": "2026-09-23T21:36:09.342Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/12838f3eef3e4b4b9c92c066ec0837b9.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/12838f3eef3e4b4b9c92c066ec0837b9"}}, "title": "Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.", "authors": [{"family": "Metheny", "given": "Leland", "initials": "L"}, {"family": "Callander", "given": "Natalie S", "initials": "NS"}, {"family": "Hall", "given": "Aric C", "initials": "AC"}, {"family": "Zhang", "given": "Mei-Jei", "initials": "MJ"}, {"family": "Bo-Subait", "given": "Khalid", "initials": "K"}, {"family": "Wang", "given": "Hai-Lin", "initials": "HL"}, {"family": "Agrawal", "given": "Vaibhav", "initials": "V"}, {"family": "Al-Homsi", "given": "A Samer", "initials": "AS"}, {"family": "Assal", "given": "Amer", "initials": "A"}, {"family": "Bacher", "given": "Ulrike", "initials": "U"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Bejanyan", "given": "Nelli", "initials": "N"}, {"family": "Bhatt", "given": "Vijaya Raj", "initials": "VR"}, {"family": "Bredeson", "given": "Chris", "initials": "C"}, {"family": "Byrne", "given": "Michael", "initials": "M"}, {"family": "Cairo", "given": "Mitchell", "initials": "M"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "DeFilipp", "given": "Zachariah", "initials": "Z"}, {"family": "Perez", "given": "Miguel Angel Diaz", "initials": "MAD"}, {"family": "Freytes", "given": "C\u00e9sar O", "initials": "CO"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Grunwald", "given": "Michael R", "initials": "MR"}, {"family": "Hashmi", "given": "Shahrukh", "initials": "S"}, {"family": "Hildebrandt", "given": "Gerhard C", "initials": "GC"}, {"family": "Inamoto", "given": "Yoshihiro", "initials": "Y"}, {"family": "Kanakry", "given": "Christopher G", "initials": "CG"}, {"family": "Kharfan-Dabaja", "given": "Mohamed A", "initials": "MA"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Lee", "given": "Jong Wook", "initials": "JW"}, {"family": "Nathan", "given": "Sunita", "initials": "S"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Ringd\u00e9n", "given": "Olov", "initials": "O"}, {"family": "Rizzieri", "given": "David", "initials": "D"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Savoie", "given": "Mary Lynn", "initials": "ML"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "van der Poel", "given": "Marjolein", "initials": "M"}, {"family": "Verdonck", "given": "Leo F", "initials": "LF"}, {"family": "Wagner", "given": "John L", "initials": "JL"}, {"family": "Yared", "given": "Jean A", "initials": "JA"}, {"family": "Hourigan", "given": "Christopher S", "initials": "CS"}, {"family": "Kebriaei", "given": "Partow", "initials": "P"}, {"family": "Litzow", "given": "Mark", "initials": "M"}, {"family": "Sandmaier", "given": "Brenda M", "initials": "BM"}, {"family": "Saber", "given": "Wael", "initials": "W"}, {"family": "Weisdorf", "given": "Daniel", "initials": "D"}, {"family": "de Lima", "given": "Marcos", "initials": "M"}], "type": "journal article", "published": "2021-11-00", "journal": {"title": "Transplant Cell Ther", "issn": "2666-6367", "volume": "27", "issue": "11", "pages": "923.e1-923.e12", "issn-l": null}, "abstract": "Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 868 allogeneic hematopoietic cell transplantations (allo-HCTs) performed between 1990 and 2004 showed a 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%, respectively. Modern supportive care, graft-versus-host disease prophylaxis, and reduced-intensity conditioning (RIC) regimens have led to improved outcomes. Therefore, the CIBMTR analyzed 1531 allo-HCTs performed in adults with t-MDS (n = 759) or t-AML (n = 772) between and 2000 and 2014. The median age was 59 years (range, 18 to 74 years) for the patients with t-MDS and 52 years (range, 18 to 77 years) for those with t-AML. Twenty-four percent of patients with t-MDS and 11% of those with t-AML had undergone a previous autologous (auto-) HCT. A myeloablative conditioning (MAC) regimen was used in 49% of patients with t-MDS and 61% of patients with t-AML. Nonrelapse mortality at 5 years was 34% (95% confidence interval [CI], 30% to 37%) for patients with t-MDS and 34% (95% CI, 30% to 37%) for those with t-AML. Relapse rates at 5 years in the 2 groups were 46% (95% CI, 43% to 50%) and 43% (95% CI, 40% to 47%). Five-year OS and DFS were 27% (95% CI, 23% to 31%) and 19% (95% CI, 16% to 23%), respectively, for patients with t-MDS and 25% (95% CI, 22% to 28%) and 23% (95% CI, 20% to 26%), respectively, for those with t-AML. In multivariate analysis, OS and DFS were significantly better in young patients with low-risk t-MDS and those with t-AML undergoing HCT with MAC while in first complete remission, but worse for those with previous auto-HCT, higher-risk cytogenetics or Revised International Prognostic Scoring System score, and a partially matched unrelated donor. Relapse remains the major cause of treatment failure, with little improvement seen over the past 2 decades. These data mandate caution when recommending allo-HCT in these conditions and indicate the need for more effective antineoplastic approaches before and after allo-HCT.", "doi": "10.1016/j.jtct.2021.08.010", "pmid": "34428556", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1742609"}, {"db": "pmc", "key": "PMC9064046"}, {"db": "pii", "key": "S2666-6367(21)01146-5"}], "notes": [], "created": "2026-09-23T10:06:02.768Z", "modified": "2026-09-23T10:06:02.801Z"}